# Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation

> **NCT07698080** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hematology department of the 920th hospital** · enrollment: 60 (estimated)

## Conditions studied

- Leukemia
- Lymphoma
- Thalassemia
- Aplastic Anemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** Intravenous Immunoglobulin
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Mononuclear Cells

## Key facts

- **NCT ID:** NCT07698080
- **Lead sponsor:** Hematology department of the 920th hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-03
- **Primary completion:** 2028-07-03
- **Final completion:** 2028-07-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07698080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07698080, "Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07698080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*